however, it is clear that the syndrome is associated with metabolic syndrome, obesity, or other comorbidities (4, 5)
To receive FDA approval, a biosimilar must: Be administered in the same way Have the same strength and dosage form Carry the same potential side effects These strict standards ensure biosimilars deliver the same safety and effectiveness patients expect from the reference biologic
Thiazide diuretics, potassium, and the development of diabetes: a quantitative review
Arctikos forced-air cooling ensures uniform stability across every shelf, protecting GLP-1 therapies from hidden hot or cold spots Why GLP-1 Needs a Strict Cold Chain Unlike small-molecule drugs, GLP-1 biologics are highly sensitive to handling delays and temperature extremes
A 2024 study examining weight loss plateaus observed that, for subjects taking semaglutide, weight loss began to plateau after 15 months
Semaglutide was first approved by the FDA in its injectable form (Ozempic) in 2017 and later as an oral tablet (Rybelsus) in 2019
